• Blog
  • Malignant Mesothelioma Epidemiology Market Report

    Malignant Mesothelioma Epidemiology Market Report

    Malignant Mesothelioma Epidemiology Market Report
    Report code - SRHL325 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global Malignant Mesothelioma Epidemiology Market, Dynamics, Trends, and Market Insights
    See more...

    Impact of COVID-19 on Malignant Mesothelioma Epidemiology Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Malignant Mesothelioma Epidemiology Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Global Malignant Mesothelioma Epidemiology Market is expected to grow from USD 380.2 million in 2020 to USD 540.8 million by 2026 at a CAGR of over 6.2% during the forecast period.

    Figure: Global Malignant Mesothelioma Epidemiology Market Size, 2020-2026 (USD Million)

    Wish to get a free sample report on this study? Click here.

    What is Malignant mesothelioma Epidemiology?

    Malignant mesothelioma is known as rare cancer that originates from the inner lining of the body’s serous cavities i.e., peritoneum, pleura, pericardium, and vaginal tunic of the testicle. It is caused due to asbestos exposure which can be hidden in the living area or any other object such as curtains, cardboard, toys, and board covers among others.

    Key Players

    Key players operating in the global Malignant Mesothelioma Epidemiology Market are

    • AstraZeneca plc (UK),
    • Bristol-Myers Squibb Company (The U.S),
    • F. Hoffmann-La Roche AG (Switzerland),
    • Merck & Co., Inc. (The U.S),
    • Novartis International AG (Switzerland),
    • Pfizer Inc. (The U.S),
    • Sanofi S.A. (France),
    • Eli Lilly and Company (The U.S),
    • Teva Pharmaceutical Industries Ltd (Israel),
    • C.H. Boehringer Sohn AG & Ko. KG (Germany),
    • Mylan N.V. (The U.S),
    • Fresenius Kabi AG (Germany) and
    • Sun Pharmaceuticals Industries Ltd (India).

    Market Dynamics

    The growth of the global malignant mesothelioma epidemiology market is primarily driven by increasing cases of mesothelioma cancer due to asbestos exposure.

    • Millions of people are around the world are exposed to asbestos. Additionally, the rising geriatric populace across geographies is expected to add to the market growth substantially.
    • Furthermore, the growing emphasis on the development of more advanced cancer treatment methods is likely to drive the market growth at a significant rate during the review period.

    Segment Analysis

    Drug Type Trends

    Based on drug type, the market has been segmented into pemetrexed, cisplatin, carboplatin, gemcitabine, vinorelbine, and others.

    The pemetrexed segment accounted for the largest market share in 2020 and is expected to register significant growth over the forecast period. The segment growth can be attributed to the increasing use of pemetrexed drugs in combination with other drugs.

    Regional Trends

    Geographically, the market in North America accounted for the largest market share in 2020 and is expected to continue its dominance over the forecast period owing to the increasing incidence of cancer disease.

    • Additionally, high spending on R&D activities to develop advanced therapies to treat cancer is likely to add to the market growth significantly.
    • The market in Asia-Pacific is expected to register healthy CAGR during the review period on account of the increasing prevalence of cancer and raising awareness about the available cancer treatment methods.

    COVID-19 Impact on Global Malignant Mesothelioma Epidemiology Market

    The covid-19 outbreak posed significant challenges to the health care system across geographies. It affected the growth of the malignant mesothelioma epidemiology market negatively as patients postponed their treatment due to a rapid surge in covid-19 cases across geographies. Also, supply chain disruptions due to the imposition of lockdown affected the installation of equipment in the hospital and thus, affected the market growth.

    Critical Questions Answered in the Report

    • What are the key trends in the global Malignant Mesothelioma Epidemiology market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of the COVID-19 on global Malignant Mesothelioma Epidemiology market?
    • What are the key strategies adopted by the major vendors to lead in the global Malignant Mesothelioma Epidemiology market?
    • What is the market share of the top vendors?

    Wish to know more about the study? Click here.

    Target Audience

    • Malignant mesothelioma epidemiology manufacturers
    • Malignant mesothelioma epidemiology suppliers
    • Malignant mesothelioma epidemiology distributors
    • Organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    The malignant mesothelioma epidemiology market size is expected to reach USD 540.8 million in the foreseeable future.

    AstraZeneca plc (UK), Bristol-Myers Squibb Company (The U.S), F. Hoffmann-La Roche AG (Switzerland), Merck & Co., Inc. (The U.S), Novartis International AG (Switzerland), Pfizer Inc. (The U.S), Sanofi S.A. (France), Eli Lilly and Company (The U.S), Teva Pharmaceutical Industries Ltd (Israel), C.H. Boehringer Sohn AG & Ko. KG (Germany), Mylan N.V. (The U.S), Fresenius Kabi AG (Germany) and Sun Pharmaceuticals Industries Ltd (India) are among the key players in the malignant mesothelioma epidemiology market.

    The malignant mesothelioma epidemiology market is expected to witness an impressive growth of 6.2% CAGR in the coming years.

    North America is expected to remain dominant in the malignant mesothelioma epidemiology market during the next five years.

    The pemetrexed segment accounted for the largest market share in 2020 and is expected to register significant growth.

    Increasing cases of mesothelioma cancer due to asbestos exposure, rising geriatric populace across geographies, growing emphasis on the development of more advanced cancer treatment methods are the factors driving the growth of malignant mesothelioma epidemiology market.

    Malignant mesothelioma epidemiology manufacturers, Malignant mesothelioma epidemiology suppliers, Malignant mesothelioma epidemiology distributors, Organizations, Government bodies are the target audience in te malignant mesothelioma epidemiology market.

    •